CancerVAX, Inc., a pre-clinical biotechnology company on a mission to develop powerful immunotherapy cancer treatments, is proud to announce that CEO Ryan Davies recently shared insights on how patents can open doors for ambitious early-stage development projects with Todd Kinard, a specialist in protecting biotech inventions. By leveraging the power of patents, CancerVAX is aiming to revolutionize the fight against cancer and bring hope to those affected by the disease.
Mr. Kinard is a highly accomplished and experienced intellectual property attorney specializing in patents, trademarks, copyrights, and related intellectual property transactions. His expertise extends to a wide range of fields, including biotechnology, chemistry, toxicology, genetics, and virology. He has held in-house corporate and patent counsel positions with several privately held companies, and has done an impressive job of constructing and managing sizeable IP portfolios.
During the discussion, Mr. Kinard shed light on the intricate workings of patents in the biotech field and explained how innovative companies, such as CancerVAX, can safeguard their groundbreaking projects from the early stages of development. With patents, biotech firms are granted the exclusive right to commercialize their invention without infringing on the intellectual property of others. Moreover, patents also ensure that the same invention can’t be sold by anyone else for a period of 20 years from the time of filing with the U.S. Patent and Trademark Office.
CEO of CancerVAX, Ryan Davis, understands the complexity of filing a patent for a new drug and both the time and money investments required to develop transformative therapies. To ensure the benefit of their shareholders, Davis says, “We must protect our work as much as possible given the magnitude of our efforts.”
At CancerVAX, Inc. we are on a mission to revolutionize the way cancer is treated. We are developing immunotherapy treatments that use the body’s own immune system to fight cancer. Our cutting-edge bioengineering and molecular technologies are being used to develop a breakthrough universal cancer vaccine (UCV). By training the body to recognize and destroy cancer cells, our UCV could one day make treating cancer as easy as getting a flu shot. Currently, we are working with UCLA to develop a UCV as well as conventional immunotherapies to treat Ewing Sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults. We plan to partner with leading researchers and institutions to build a strong portfolio of cancer vaccines, and ultimately become a dominate player in the immunotherapy space. Together we can create a future of cancer care that is accessible and effective.